Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Idefirix Market Size, Value And Growth Trajectory Through 2030
The historical period’s growth can be attributed to the scarcity of organs for kidney transplantation, the significant prevalence of donor-specific antibodies, the inherent limitations of traditional desensitization methods, the promising early clinical success of imlifidase, and the expansion in transplant centers.
Projected growth throughout the forecast period is primarily driven by an escalating demand for kidney transplants, the expansion of transplant waiting lists, the increasing adoption of precision immunology, the presence of supportive regulatory pathways, and the proliferation of specialized transplant clinics. Concurrently, major trends anticipated in this period include a rising application of desensitization therapies in transplantation, an intensified focus on highly sensitized patients, the broadening of enzyme-based immunomodulation, an increase in kidney transplant volumes, and enhanced access to advanced transplant care.
Get A Free Sample Report With In-Depth Market Insights:
Idefirix Market Expansion Drivers: What’s Shaping Future Growth?
The escalating prevalence and incidence of kidney diseases are anticipated to stimulate the expansion of the idefirix market moving forward. Kidney diseases are conditions characterized by damage to the kidneys’ function or structure, thereby impeding their capacity to filter waste and maintain fluid balance within the body. This rise in the occurrence of kidney ailments can be attributed to factors such as an aging demographic, increasing rates of diabetes and hypertension, lifestyle choices, and genetic predispositions. Idefirix, an innovative immunoglobulin G (IgG)-degrading enzyme therapy, offers assistance to kidney disease patients by making it possible for highly sensitized individuals to undergo essential kidney transplants, as it effectively diminishes donor-specific antibodies that would otherwise trigger transplant rejection. As an illustration, in June 2023, a report from Kidney Research, a research organization based in the UK, projected that the incidence of acute kidney injury would increase from an estimated 615,000 cases in 2022 to 637,000 by 2033. Hence, the growing prevalence and incidence of kidney diseases are propelling the idefirix market’s growth.
Idefirix Market Segment Outlook: Which Categories Are Growing Fastest?
The idefirix market covered in this report is segmented –
1) By Patient Demographics: Pediatric Patients, Adult Patients
2) By Application: Kidney Transplantation, Desensitization Protocols
3) By End-User: Hospitals, Specialized Clinics, Home Healthcare
4) By Distribution Channel: Direct Sales, Pharmacies
Idefirix Market Strategic Trends: What Defines The Next Growth Phase?
A significant trend in the idefirix market centers on developing innovative solutions, such as desensitization treatment, to address highly sensitized kidney transplant patients. Desensitization treatment is a medical process designed to eliminate or reduce harmful antibodies, thereby enabling transplant recipients to receive organs from incompatible donors. For instance, in July 2023, Hansa Biopharma, a biopharmaceutical company based in Sweden, announced that the Australian Therapeutic Goods Administration (TGA), an Australia-based regulatory authority, had approved Idefirix (imlifidase) as a desensitization treatment for highly sensitized kidney transplant patients. This approval allows these patients to obtain kidney transplants from both living and deceased donors. The treatment operates by diminishing or removing harmful anti-donor antibodies, which could otherwise prevent successful transplantation. Based on positive findings from Hansa Biopharma’s phase 2 studies, this authorization signifies a major advancement in enhancing kidney transplant options for highly sensitized patients in Australia.
Idefirix Market Leading Companies And Competitive Benchmarking
Major companies operating in the idefirix market are Hansa Biopharma AB
View The Full Idefirix Market Report:
Idefirix Market Regional Analysis: Which Region Leads By Revenue?
Europe was the largest region in the idefirix market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the idefirix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
